

31 March 2025

Treatment of breast and ovarian cancers

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of October 2024 to the end of December 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Health and Social Care Trust.

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	99
1.2 Alpelisib (Piqray)	<5
1.3 Elacestrant (Orserdu)	<5
1.4 Fulvestrant (fulvestrant or Faslodex)	43
1.5 Inavolisib (Inaqovi)	<5
1.6 Palbociclib (Ibrance)	96
1.7 Ribociclib (Kisqali)	54
1.8 Capivasertib (Truqap)	<5
1.9 Talazoparib (Talzenna)	<5
1.10 Olaparib (Lynparza)	<5

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Not available

Name of combination or monotherapy	Number patients treated

31 March 2025

2.1 Abemaciclib (Verzenios)	Not available
2.2 Ribociclib (Kisqali)	Not available
2.3 Olaparib (Lynparza)	Not available

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available?

Not available

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	Not available
3.2 Ribociclib (Kisqali)	Not available

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	12
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	15
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	9

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024?

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	<5
5.2 Locally advanced or metastatic breast cancer	Not available

OVARIAN CANCER and ENDOMETRIAL CANCER

31 March 2025

Q6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Niraparib (Zejula)	9
6.2 Rucaparib (Rubraca)	<5
6.3 Olaparib (Lynparza)	<5

Q7. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Olaparib in total	<5
7.2 Olaparib monotherapy	<5
7.3 Olaparib + bevacizumab in combination	<5
7.4 Bevacizumab total	17
7.5 Bevacizumab monotherapy	<5
7.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	17

Q8. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	<5
8.2 Pembrolizumab (Keytruda)	<5
8.3 Lenvatinib (Lenvima)	<5

31 March 2025

Q9. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available?

Name of medicine	Number patients treated
9.1 Dostarlimab monotherapy	<5
9.2 Dostarlimab in combination with Chemotherapy	<5
9.3 Pembrolizumab monotherapy	<5
9.4 Pembrolizumab + Lenvatinib in combination	5
9.5 Lenvatinib monotherapy	<5

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.